# Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

> **NCT06931080** · PHASE2,PHASE3 · RECRUITING · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 630 (estimated)

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** EB-1020 (Centanafadine) 164.4 mg
- **DRUG:** EB-1020 (Centanafadine) 328.8 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06931080
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 630 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06931080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06931080, "Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06931080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*